Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226938 | 0.86 | CHEK1 (0.42) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL9256410 | 0.81 | CHKA (0.38) | HTTCHKAMEN1KMT2A | |
| SCHEMBL297213 | 0.79 | AR (0.33) | MAPTALDH1A1TSHRKDM1AL3MBTL1 | |
| SCHEMBL9830323 | 0.79 | ELANE (0.32) | — | |
| SCHEMBL2254662 | 0.77 | MCL1 (0.39) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL296148 | 0.76 | KDM4E (0.33) | MAPTALDH1A1CYP1A2KDM4ECYP2C19 | |
| SCHEMBL293332 | 0.76 | GAA (0.56) | MAPTSMN1; SMN2POLBLMNANPSR1 | |
| SCHEMBL8800532 | 0.75 | CHEK1 (0.40) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL3903119 | 0.73 | KDM4E (0.30) | MAPTGAAKDM4E | |
| SCHEMBL298360 | 0.73 | ELANE (0.38) | MAPTHTTLMNANPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | claimed |
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | claimed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | claimed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | claimed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | claimed |
| EP-1218383-B1 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-11-05 | — | — | EP | claimed |
| EP-1682076-A4 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS INC (US) | 2008-02-06 | — | — | EP | claimed |
| US-20070020793-A1 | Three-dimensional shaped solid dosimeter and method of use | ADAMOVICS JOHN A | 2007-01-25 | — | — | US | claimed |
| CN-1898205-A | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AG (DE) | 2007-01-17 | — | — | CN | claimed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | claimed |
| EP-1218383-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2002030428-A1 | USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | claimed |
| WO-2001081344-A1 | SALTS OF BICYCLIC, N-ACYLATED IMIDAZO-3-AMINES AND IMIDAZO-5-AMINES | Grünenthal GmbH (DE) | 2001-11-01 | — | — | WO | claimed |
| WO-2001027118-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| WO-2001027119-A2 | SUBSTANCE LIBRARY CONTAINING BICYCLIC IMIDAZO-5-YL-AMINES AND/OR BICYCLIC IMIDAZO-3-YL-AMINES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| EP-0605286-B1 | Thermal-dye-bleach construction | MINNESOTA MINING & MFG (US) | 1998-06-24 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0605286-A1 | Thermal-dye-bleach construction | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-07-06 | — | — | EP | claimed |
| US-5314795-A | Thermal-dye-bleach construction comprising a polymethine dye and a thermal carbanion-generating agent | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | CHEK1 3689/4885NEK2 1675/4885LIMK1 1159/4885 |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | CHEK1 3158/4885NEK2 538/4885LIMK1 3821/4885 |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | CHEK1 2347/4885NEK2 1183/4885LIMK1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.